Radio Frequency Models of Novae in eruption. I. The Free-Free Process in Bipolar Morphologies

Observations of novae at radio frequencies provide us with a measure of the total ejected mass, density profile and kinetic energy of a nova eruption. The radio emission is typically well characterized by the free-free emission process. Most models to date have assumed spherical symmetry for the eruption, although it has been known for as long as there have been radio observations of these systems, that spherical eruptions are to simplistic a geometry. In this paper, we build bipolar models of the nova eruption, assuming the free-free process, and show the effects of varying different parameters on the radio light curves. The parameters considered include the ratio of the minor- to major-axis, the inclination angle and shell thickness (further parameters are provided in the appendix). We also show the uncertainty introduced when fitting spherical model synthetic light curves to bipolar model synthetic light curves. We find that the optically thick phase rises with the same power law ($S_{\nu} \propto t^2$) for both the spherical and bipolar models. In the bipolar case there is a "plateau" phase -- depending on the thickness of the shell as well as the ratio of the minor- to major-axis -- before the final decline, that follows the same power law ($S_{\nu} \propto t^{-3}$) as in the spherical case. Finally, fitting spherical models to the bipolar model synthetic light curves requires, in the worst case scenario, doubling the ejected mass, more than halving the electron temperature and reducing the shell thickness by nearly a factor of 10. This implies that in some systems we have been over predicting the ejected masses and under predicting the electron temperature of the ejecta.Comment: 9 pages, 6 figures, accepted for publication in ApJ, accompanying movie to figure 3 available at http://www.ast.uct.ac.za/~valerio/papers/radioI

The Distance to Nova V959 Mon from VLA Imaging

Determining reliable distances to classical novae is a challenging but crucial step in deriving their ejected masses and explosion energetics. Here we combine radio expansion measurements from the Karl G. Jansky Very Large Array with velocities derived from optical spectra to estimate an expansion parallax for nova V959 Mon, the first nova discovered through its gamma-ray emission. We spatially resolve the nova at frequencies of 4.5-36.5 GHz in nine different imaging epochs. The first five epochs cover the expansion of the ejecta from 2012 October to 2013 January, while the final four epochs span 2014 February to 2014 May. These observations correspond to days 126 through 199 and days 615 through 703 after the first detection of the nova. The images clearly show a non-spherical ejecta geometry. Utilizing ejecta velocities derived from 3D modelling of optical spectroscopy, the radio expansion implies a distance between 0.9 +/- 0.2 and 2.2 +/- 0.4 kpc, with a most probable distance of 1.4 +/- 0.4 kpc. This distance implies a gamma-ray luminosity much less than the prototype gamma-ray-detected nova, V407 Cyg, possibly due to the lack of a red giant companion in the V959 Mon system. V959 Mon also has a much lower gamma-ray luminosity than other classical novae detected in gamma-rays to date, indicating a range of at least a factor of 10 in the gamma-ray luminosities for these explosions.Comment: 11 pages, 8 figures, 3 tables, submitted to ApJ 2015-01-21, under revie

Particle size segregation in granular flow in silos

Segregation and layering of alumina in storage silos are investigated, with a view to predicting output quality versus time, given known variations in input quality on emplacement. A variety of experiments were conducted, existing relevant publications were reviewed, and the basis for an algorithm for predicting the effect of withdrawing from a central flowing region, in combination with variations in quality due to geometric, layering and segregation effects, is described in this report

The Impact of Differential Cost Sharing of Non-Steroidal Anti-Inflammatory Agents on the Use and Costs of Analgesic Drugs

OBJECTIVE: To estimate the effect of differential cost sharing (DCS) schemes for non-steroidal anti-inflammatory drugs (NSAIDs) on drug subsidy program and beneficiary expenditures. DATA SOURCES/STUDY SETTING: Monthly aggregate claims data from Pharmacare, the public drug subsidy program for seniors in British Columbia, Canada over the period 1989-11 to 2001-06. STUDY DESIGN: DCS limits insurance reimbursement of a group of therapeutically similar drugs to the cost of the lowest priced drugs, with beneficiaries responsible for costs above the reimbursement limit. Pharmacare introduced two different forms of DCS, generic substitution (GS) and reference pricing (RP), in April 1994 and November 1995, respectively, to the NSAIDs. Under GS, generic and brand versions of the same NSAID are considered interchangeable, whereas under RP different NSAIDs are. We extrapolated average reimbursement per day of NSAID therapy over the months before GS and RP to estimate what expenditures would have been without the policies. These counterfactual predictions were compared to actual values to estimate the impact of the policies; the estimated impacts on reimbursement rates were multiplied by the post-policy volume of NSAIDS dispensed, which appeared unaffected by the policies, to estimate expenditure changes. DATA COLLECTION: The cleaned NSAID claims data, obtained from Pharmacare’s databases, were aggregated by month and by their reimbursement status under the GS and RP policies. PRINCIPAL FINDINGS: After RP, program expenditures declined by $22.7 million, or$4 million annually, cutting expenditure by half. Most savings accrued from the substitution of low cost NSAIDs for more costly alternatives. About 20% of savings represented expenditures by seniors who elected to pay for partially-reimbursed drugs. GS produced one quarter the savings of RP. CONCLUSIONS: RP of NSAIDs achieved its goal of reducing drug expenditures and was more effective than GS. The effects of RP on patient health and associated health care costs remain to be investigated.Reference pricing; generic substitution; prescription drugs; drug cost containment; NSAIDs.

BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer

In sporadic epithelial ovarian cancer (EOC), the inactivation of BRCA1 through various mechanisms is a relatively common event. BRCA1 protein dysfunction results in the breakdown of various critical pathways in the cell, notably, the DNA damage response and repair pathway. Tumors from patients with BRCA1 germline mutations have an increased sensitivity to DNA damaging chemotherapeutic agents, such as cisplatin, due to defective DNA repair. Thus, inhibiting BRCA1 in sporadic EOC using novel targeted therapies is an attractive strategy for the treatment of advanced or recurrent EOC. Several classes of small molecule inhibitors that affect BRCA1 have now been tested in preclinical and clinical studies suggesting that this is a rational therapeutic approach. The aim of this paper is to provide an understanding of how BRCA1 has evolved into a promising target for the treatment of sporadic disease and to outline the main potential small molecule inhibitors of BRCA1 in EOC

The role of the Berry Phase in Dynamical Jahn-Teller Systems

The presence/absence of a Berry phase depends on the topology of the manifold of dynamical Jahn-Teller potential minima. We describe in detail the relation between these topological properties and the way the lowest two adiabatic potential surfaces get locally degenerate. We illustrate our arguments through spherical generalizations of the linear T x h and H x h cases, relevant for the physics of fullerene ions. Our analysis allows us to classify all the spherical Jahn-Teller systems with respect to the Berry phase. Its absence can, but does not necessarily, lead to a nondegenerate ground state.Comment: revtex 7 pages, 2 eps figures include

Outcomes of a remote, decentralized health center-based HIV/AIDS antiretroviral program in Zambia, 2003 to 2007

A cross-sectional study of patients living with HIV/ AIDS treated during 2003 to 2007 in decentralized, rural health centers in Zambia was performed to measure virological outcomes after 12 months of antiretroviral therapy and identify factors associated with virological failure. Data from 228 patients who started antiretroviral therapy >12 months prior were analyzed. In all, 93% received stavudine + lamivudine + nevirapine regimens, and median antiretroviral therapy duration was 23.5 months (interquartile range 20-28). Of the 205 patients tested for viral load, 177 (86%) had viral load <1000 copies/mL. Probability of developing virological failure (viral load >1000 copies/mL) was 8.9% at 24 months and 19.6% at 32 months. Predictors for virological failure were <100% adherence, body mass index <18.5 kg/m(2), and women <40 years old. Of those with virological failure who underwent 3 to 6 months of intensive adherence counseling, 45% obtained virological success. In a remote, resource-limited setting in decentralized health centers, virological and immunological assessments of patients on antiretroviral therapy >12 months showed that positive health outcomes are achievable